Canopy Growth (NYSE:CGC) and Foamix Pharmaceuticals (FOMX) Head to Head Review

Canopy Growth (NYSE:CGC) and Foamix Pharmaceuticals (NASDAQ:FOMX) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings and risk.

Analyst Ratings

This is a summary of recent ratings for Canopy Growth and Foamix Pharmaceuticals, as reported by MarketBeat.com.

Canopy Growth currently has a consensus target price of $64.82, suggesting a potential upside of 43.08%. Foamix Pharmaceuticals has a consensus target price of $17.00, suggesting a potential upside of 553.85%. Given Foamix Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts clearly believe Foamix Pharmaceuticals is more favorable than Canopy Growth.

Volatility and Risk

Canopy Growth has a beta of 4.17, meaning that its stock price is 317% more volatile

... read more at: https://rocklandregister.com/2019/05/15/head-to-head-survey-canopy-growth-cgc-foamix-pharmaceuticals-fomx.html

Leave a Reply